FDA issues warning to Hologic, citing manufacturing and safety violations for BioZorb devices. Patient safety risks and reporting failures highlighted ...

The U.S. Food and Drug Administration has sent a warning letter to Marlborough, Mass.-based medical technology company ...

Hologic Inc. has received a warning letter from the Food and Drug Administration regarding its BioZorb product line, even ...

Hologic stopped manufacturing the device after reports of serious adverse events in patients who had the markers implanted in breast tissue.

The court concluded genuine issues of material fact existed regarding whether an advanced warning of the alleged risks of a ...

BioZorb, a medical device manufacturer, could not dodge the majority of the negligence and breach of warranty claims brought ...

HOLX touched a new yearly low this week, reflecting market reaction to its mixed Q1 fiscal 2025 results. Still, the stock offers strong rebound potential.

Enough evidence for jury to consider failure to warn claim Case is one of nearly two dozen Hologic faces over BioZorb Hologic Inc. can’t shake a woman’s suit alleging the medical device manufacturer ...

Evercore ISI lowered the firm’s price target on Hologic (HOLX) to $76 from $81 and keeps an In Line rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and ...